COVID-19 infection in CVID patients: What we know so far.
COVID-19 infection in CVID patients: What we know so far.
复制标题
CVID患者的COVID-19感染：我们目前所知道的
DOI：
10.1002/iid3.450
复制
发表时间：
2021-09
期刊：
影响因子：
--
通讯作者：
Lötters S
中科院分区：
文献类型：
--
作者：
Weifenbach N;Jung A;Lötters S
在常见的可变免疫缺陷(CVID)患者中，免疫反应受到损害。脑血管病患者对新冠肺炎的了解很少。在这里，我们综合了目前关于新冠肺炎对脑血管疾病患者构成威胁的程度和最著名的治疗方法的研究。对14种出版物进行了综述。与新冠肺炎感染的一般情况相比，具有中到重度(~29%)和危重感染病程(~10%)的CVID患者的数量和死亡病例(~13%)都有所增加。然而，这可能是高估了。缺乏系统的全队列研究，CVID患者中出现的无症状或轻微病例很容易被忽视。几乎所有患者都接受了定期免疫球蛋白替代治疗，这可能解释了为什么危重和死亡病例的数量没有更高。此外，恢复期血浆的应用被证明具有积极的效果。新冠肺炎对脑血管疾病患者构成了更高的威胁。然而，只有系统的研究才能提供关于这一威胁程度的可靠信息。常规的免疫球蛋白替代治疗有利于对抗脑血管病患者的新冠肺炎，感染后的最佳治疗包括在常规药物治疗的基础上使用恢复期血浆。
In patients with common variable immunodeficiency (CVID), immunological response is compromised. Knowledge about COVID‐19 in CVID patients is sparse. We, here, synthesize current research addressing the level of threat COVID‐19 poses to CVID patients and the best‐known treatments. Review of 14 publications. The number of CVID patients with moderate to severe (~29%) and critical infection courses (~10%), and the number of fatal cases (~13%), are increased compared to the general picture of COVID‐19 infection. However, this might be an overestimate. Systematic cohort‐wide studies are lacking, and asymptomatic or mild cases among CVID patients occur that can easily remain unnoticed. Regular immunoglobulin replacement therapy was administered in almost all patients, potentially explaining why the numbers of critical and fatal cases were not higher. In addition, the application of convalescent plasma was demonstrated to have positive effects. COVID‐19 poses an elevated threat to CVID patients. However, only systematic studies can provide robust information on the extent of this threat. Regular immunoglobulin replacement therapy is beneficial to combat COVID‐19 in CVID patients, and best treatment after infection includes the use of convalescent plasma in addition to common medication.
登录
查看更多内容
DOI：
10.1016/j.jaip.2020.11.006
发表时间：
2021-01
期刊：
The journal of allergy and clinical immunology. In practice
影响因子：
--
作者：
Cohen B;Rubinstein R;Gans MD;Deng L;Rubinstein A;Eisenberg R
通讯作者：
Eisenberg R
DOI：
10.1016/j.jaci.2020.09.010
发表时间：
2021-03
期刊：
The Journal of allergy and clinical immunology
影响因子：
--
作者：
Meyts I;Bucciol G;Quinti I;Neven B;Fischer A;Seoane E;Lopez-Granados E;Gianelli C;Robles-Marhuenda A;Jeandel PY;Paillard C;Sankaran VG;Demirdag YY;Lougaris V;Aiuti A;Plebani A;Milito C;Dalm VA;Guevara-Hoyer K;Sánchez-Ramón S;Bezrodnik L;Barzaghi F;Gonzalez-Granado LI;Hayman GR;Uzel G;Mendonça LO;Agostini C;Spadaro G;Badolato R;Soresina A;Vermeulen F;Bosteels C;Lambrecht BN;Keller M;Mustillo PJ;Abraham RS;Gupta S;Ozen A;Karakoc-Aydiner E;Baris S;Freeman AF;Yamazaki-Nakashimada M;Scheffler-Mendoza S;Espinosa-Padilla S;Gennery AR;Jolles S;Espinosa Y;Poli MC;Fieschi C;Hauck F;Cunningham-Rundles C;Mahlaoui N;IUIS Committee of Inborn Errors of Immunity;Warnatz K;Sullivan KE;Tangye SG
通讯作者：
Tangye SG
影响因子：
15.8
作者：
Hauser, Anthony;Counotte, Michel J.;Riou, Julien
通讯作者：
Riou, Julien
影响因子：
14.2
作者：
Gathmann, Benjamin;Mahlaoui, Nizar;Grimbacher, Bodo
通讯作者：
Grimbacher, Bodo